David Shook

This inventor holds 4 USPTO granted patents and 1 published patent application and 1 EPO patent. Top assignees: National University of Singapore, St. Jude Children's Research Hospital. Active years: 2019-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: David Shook. Retrieved from https://idiyas.com/inventor/david-shook

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 4 (Patent Applications = 1)

% Patents Active = 100.0

EPO Patents = 1 (Patent Applications = 2)

Average Co-Inventor Count = 3.0

ph-index = 3

Forward Citations = 38(Granted Patents)

Company Filing History:

4 out of 851

National University of Singapore

patents

4 out of 281

St. Jude Children's Research Hospital

patents

where one patent can have more than one assignee

Years Active: 2019-2025

Loading Chart...

4 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12264335 - Natural killer cells expressing membrane-bound interleukin 15 (mbIL15) and uses thereof (2025-04-01),

2. 11560548 - Immune cells expressing membrane-bound interleukin 15 (mbIL15) and uses thereof (2023-01-24),

3. 10774311 - Natural killer cells modified to express membrane-bound interleukin 15 and uses thereof (2020-09-15),

4. 10428305 - Modified natural killer cells that express IL15 and uses thereof (2019-10-01),

Title: David Shook: Innovator in Cancer Treatment

Introduction

David Shook is a notable inventor based in Memphis, TN (US), recognized for his contributions to the field of cancer treatment. With a total of four patents to his name, he has made significant strides in the development of innovative therapies utilizing natural killer (NK) cells.

Latest Patents

Among his latest patents is the invention titled "Natural killer cells expressing membrane-bound interleukin 15 (mbIL15) and uses thereof." This invention provides a natural killer (NK) cell that expresses all or a functional portion of interleukin-15 (IL-15), along with methods for producing such cells. The invention further outlines methods for using these NK cells to treat cancer in subjects or to enhance the expansion and/or survival of NK cells. Another significant patent is "Immune cells expressing membrane-bound interleukin 15 (mbIL15) and uses thereof," which shares similar applications and methodologies aimed at improving cancer treatment.

Career Highlights

David Shook has worked with prestigious institutions, including the National University of Singapore and St. Jude Children's Research Hospital. His work in these organizations has contributed to advancing research in immunotherapy and cancer treatment.

Collaborations

Some of his notable coworkers include Dario Campana and Masaru Imamura, who have collaborated with him on various research projects.

Conclusion

David Shook's innovative work in the field of cancer treatment through the development of NK cell therapies showcases his commitment to advancing medical science. His contributions are paving the way for new treatment options for cancer patients.

Profile summary based on public USPTO records.